in the news
JUMP TO: featured articles ∙ press releases ∙ case studies ∙ our team
JUMP TO: featured articles ∙ press releases ∙ case studies ∙ our team
JUMP TO: featured articles ∙ press releases ∙ case studies ∙ our team
JUMP TO: featured articles ∙ press releases ∙ case studies ∙ our team
Anna has her son, Hunter, take the Allergenis test to find out how allergic he is to peanuts. Although the response may not always be what we want it to be, there is a relief that comes from knowing with certainty what your threshold is when it comes to your allergy.
Marcie & Rheya reflect on their allergy journey, and finally gain some clarity on where they stand with the severity of their allergy.
Questions, inquiries or interested in press opportunities?
Please reach out to the allergenis media team.
Americans are now more concerned about their mental health than Covid, according to a recent poll from Ipsos.
The U.S. Preventive Services Task Force, which advises the Health and Human Services Department, recommended anxiety screening for children and teenagers this month. It is taking public comment through Oct. 17 on a draft recommendation that all adults be evaluated, too.
The situation is motivating lawmakers in both parties to provide an increasingly stressed, depressed and anxious populace with the appropriate care.
Epitope testing has been shown in studies to be far more reliable in diagnosing peanut allergy than traditional skin or blood testing. Now, new research reveals that epitope testing is also good at determining if a child with peanut allergy will react to trace amounts, or if they can consume one or more peanuts before starting to react.
The epitope test is the first to provide reaction “thresholds.” These may be useful for families in deciding how careful they need to be in avoiding peanuts. This includes whether their child can safely eat foods with the “may contain” warning.
Allergenis’ bead-based epitope assay at center of study from Mount Sinai revealing breakthrough diagnostic for peanut allergy
As a toddler, Colton McClure never wanted to eat peanut butter. "He would always push it away," said his mom, Cheri McClure.
Then when he was a preschooler, Colton ate one Reese's peanut butter cup and was fine. After the second one, he threw up. "Something is not right," McClure said.
An allergy skin prick test produced a reaction to peanuts, tree nuts and shellfish.
The McClures, who live in Austin, immediately changed what they did. They wouldn't go to restaurants, for fear of cross-contamination. They looked at shampoos and soaps to make sure nothing Colton was allergic to was in them. They looked at processed foods for all his allergens and avoided them. They even called companies to ask what their protocols were at their manufacturing plants.
June 12, 2023
Data shows a new blood test provides information linked to the likelihood of anaphylaxis in peanut allergic individuals.
June 7, 2023
AllerGenis Announces Presentations at EAACI Congress 2023: Pathways From Precision Medicine to Personalized Health Care
December 29, 2022
CEO will present progress throughout 2022 and outlook for 2023. Allergenis, a commercial stage biotechnology company which aims to revolutionize the diagnosis and management of food allergy, today announced it is presenting at the upcoming Biotech Showcase™ 2023 conference, coinciding with the 41st Annual J.P. Morgan Health Care Conference in San Francisco, January 9-12, 2023.
August 2022
Maria Suprun, Paul Kearney, Clive Hayward, Heather Butler, Robert Getts, Scott H. Sicherer, Paul J. Turner, Dianne E. Campbell, Hugh A. Sampson
July 2022
Maria Suprun, Paul Kearney, Clive Hayward, Heather Butler, Robert Getts, Scott H. Sicherer, Paul Turner, Dianne E. Campbell, Hugh A. Sampson
June 2022
Sayantani B. Sindher, Andrew Long, Andrew R. Chin, Angela Hy, Vanitha Sampath, Kari C. Nadeau, R. Sharon Chinthrajah
JIM GARNER
CEO & Board Member
HUGH SAMPSON, MD
Director
PAUL KEARNEY, PHD
Product Development & Data Science
ERIN MALAWER
Medical Education